NASDAQ · CAI

Caris Life Sciences, Inc.

Healthcare · Biotechnology

$30.65▲ 2.23% ($0.67)at close

As of 4:00 PM ET

52-week

$14.19$33.66

Market cap

$8.66B

P/E

82.47

EPS (TTM)

$0.37

Next earnings

Nov 4, 2026

Valuation

Recommended · Earnings yield

Price used

$30.65

Earnings yield

1.21%

Reported earnings

10-year Treasury benchmark: 4.96%

USD · TTM earnings ending 2026-06-30

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 21, 2026, 8:00 PM UTC
Financial statement period: TTM earnings ending 2026-06-30
Data refreshed: Sep 22, 2026, 9:57 AM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Is there enough operating history to anchor a DCF? Only 1 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: -6.95%Revenue (TTM): 85.37%FCF (TTM): 204.2%

What changed

The stock fell 6.95% over the last year. Revenue grew 85.37% over the trailing twelve months. Operating margin moved from -25.82% to 15.49%. Free cash flow grew 204.2% over the trailing twelve months.

What the market seems to be pricing

The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at 15.49%. A decisive move in revenue — currently up 85.37% — would be the clearest signal to resolve the ambiguity.

Performance

Monthly returns

Company profile

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally.

CEODavid Dean Halbert

SectorHealthcare

IndustryBiotechnology

Employees1,846

IPO dateJun 18, 2025

https://www.carislifesciences.com

Market multiples

Forward P/E—

EV/EBITDA632.55

Enterprise value$7.2B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth45.38%

Gross margin (FY2025)66.4%▲23.0ppvs FY2024

Operating margin (FY2025)5.56%▲67.9ppvs FY2024

ROE20.13%

Analyst consensus

RatingBuy

Target price$26.00▼15.17%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est $0.03 · Revenue est $256.25M

View

NASDAQ · CAI

Caris Life Sciences, Inc.

Healthcare · Biotechnology

$30.65▲ 2.23% ($0.67)at close

As of 4:00 PM ET

52-week

$14.19$33.66

Market cap

$8.66B

P/E

82.47

EPS (TTM)

$0.37

Next earnings

Nov 4, 2026

Valuation

Recommended · Earnings yield

Price used

$30.65

Earnings yield

1.21%

Reported earnings

10-year Treasury benchmark: 4.96%

USD · TTM earnings ending 2026-06-30

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 21, 2026, 8:00 PM UTC
Financial statement period: TTM earnings ending 2026-06-30
Data refreshed: Sep 22, 2026, 9:57 AM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Is there enough operating history to anchor a DCF? Only 1 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: -6.95%Revenue (TTM): 85.37%FCF (TTM): 204.2%

What changed

What the market seems to be pricing

What would invalidate this read

Operating margin currently stands at 15.49%. A decisive move in revenue — currently up 85.37% — would be the clearest signal to resolve the ambiguity.

Performance

Monthly returns

Company profile

CEODavid Dean Halbert

SectorHealthcare

IndustryBiotechnology

Employees1,846

IPO dateJun 18, 2025

https://www.carislifesciences.com

Market multiples

Forward P/E—

EV/EBITDA632.55

Enterprise value$7.2B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth45.38%

Gross margin (FY2025)66.4%▲23.0ppvs FY2024

Operating margin (FY2025)5.56%▲67.9ppvs FY2024

ROE20.13%

Analyst consensus

RatingBuy

Target price$26.00▼15.17%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est $0.03 · Revenue est $256.25M

View